Novartis Ag (NVS) Revenue (2009 - 2025)

Novartis Ag has disclosed Revenue across 12 years of filings, most recently posting $54.5 billion for FY2025.

• Revenue for Q2 2025 came in at $14.1 billion, up 12.32% year-over-year; the trailing twelve-month figure through Jun 2025 was $73.1 billion (up 57.27% YoY), and the FY2025 annual result was $54.5 billion, up 8.38% from the prior year.
• Revenue came in at $54.5 billion for FY2025 at Novartis Ag, up from $50.3 billion in the prior year.
• In the past five years, Revenue ranged from a high of $54.5 billion in FY2025 to a low of $42.2 billion in FY2022.
• The 5-year median for Revenue is $45.4 billion (2023), against an average of $47.1 billion.
• Across the five-year window, Revenue declined 12.08% in 2021 and increased 10.73% in 2024, its largest moves.
• Novartis Ag's Revenue stood at $42.8 billion in 2021, then fell by 1.34% to $42.2 billion in 2022, then climbed by 7.66% to $45.4 billion in 2023, then gained by 10.73% to $50.3 billion in 2024, then gained by 8.38% to $54.5 billion in 2025.
• The last three Revenue figures came in at $54.5 billion (FY2025), $50.3 billion (FY2024), and $45.4 billion (FY2023), per Business Quant data.